Company Overview
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Why Investors Should Care
Trades at a P/E of 0.2, below the sector median of 22.2.
Carries low leverage with a debt-to-equity ratio of 0.24.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -97.12% |
| 6 Months: | -76.84% |
| 3 Months: | -67.51% |
| 1 Month: | -11.64% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)37.23 · Neutral
P/E of 0.20 is below the sector median of 22.16 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 97.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Basic Materials).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NXTS Nexentis Technologies Inc. | 1.67 | 0.20 | $2.43M | 0.00% | -28.29% | - | - | - |
| 2 | LIN Linde plc NDXSPXR3K | 468.38 | 30.22 | $215.91B | 1.40% | 12.46% | 18.40% | 13.90% | 18.47% |
| 3 | SCCO Southern Copper Corporation R3K | 208.56 | 31.27 | $176.10B | 2.24% | 36.40% | 49.90% | 8.32% | 3.80% |
| 4 | NEM Newmont Corporation SPXR3K | 127.09 | 16.01 | $133.91B | 0.84% | - | 25.91% | 6.53% | 20.15% |
| 5 | RIO Rio Tinto Group | 103.83 | 14.07 | $130.27B | 4.78% | 13.65% | 19.31% | 1.24% | -7.00% |
| 6 | FCX Freeport-McMoRan Inc. SPXR3K | 76.62 | 37.56 | $110.03B | 0.78% | 12.50% | 14.75% | 1.35% | -1.26% |
| 7 | AEM Agnico Eagle Mines Limited | 201.84 | 17.27 | $102.20B | 0.88% | 19.78% | 22.97% | 27.53% | 88.11% |
| 8 | SHW The Sherwin-Williams Company SPXR3K | 326.09 | 30.05 | $79.16B | 1.00% | 21.93% | 65.12% | 6.18% | 8.26% |
| 9 | ECL Ecolab Inc. SPXR3K | 278.11 | 37.33 | $77.96B | 1.05% | 15.10% | 21.96% | 6.55% | 9.74% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 129.73K | - | - | 63.57K | - | - | 123.07K | 54.40K | 71.36K | 87.63K | 31.08K | 51.23K | 121.01K | 36.61K | - | 44.00K | 17.00K | 9.00K | - | 0 | 0 | 2.00K | -68.00K | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54.48K | 14.00K | 2.00K | 2.00K | - | - |
| Gross Profit | 95.69K | -64.99K | - | 42.79K | -4.91K | - | 120.14K | 43.05K | 17.72K | 45.78K | 18.08K | 26.83K | 78.26K | 9.60K | - | 16.00K | 11.00K | -68.00K | 86.04K | 52.00K | -2.00K | 0 | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 503.00K | 2.83M | 1.33M | 538.00K | 2.28M |
| Operating Income | -345.84K | -528.37K | -504.73K | -361.86K | -403.73K | -432.08K | -246.88K | -1.62M | -1.29M | -1.35M | -1.28M | -1.77M | -1.74M | -840.32K | -2.86M | -899.00K | -847.00K | -1.44M | - | -503.00K | -2.83M | -1.33M | -587.00K | -2.28M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -397.00K | -3.35M | -1.32M | 1.34M | -7.24M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 716.00K | 1.20M | - | - | 100.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.12M | -4.55M | 370.00K | 1.83M | -7.45M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | - | - | - | -23.00K |
| Net Income | -355.76K | -537.42K | -514.25K | -365.65K | -577.04K | -433.90K | -492.40K | -1.48M | -1.29M | -1.33M | -1.26M | -1.76M | -1.71M | -709.50K | -2.37M | -769.00K | -787.00K | -2.26M | - | -1.19M | -4.51M | 429.00K | 1.27M | -6.58M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.44 | -3.15 | -2.46 | -0.69 | -1.78 | -0.26 | -0.23 | -0.39 | - | -85.28 | -44.10 | 3.15 | - | -10.74 |
| R&D Expense | 131.83K | 87.18K | 152.40K | 157.64K | 95.71K | 87.47K | 69.79K | 226.74K | 66.47K | 209.36K | 113.38K | 198.50K | 118.91K | 16.86K | 1.69M | 116.00K | 6.00K | 19.00K | - | 20.00K | 9.00K | 52.00K | - | 275.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 426.59K | 175.82K | 232.27K | - | 394.00K | 263.00K | 0 | 0 |
| Cost of Revenue | - | - | - | 135.94K | 158.31K | 55.00K | 165.00K | - |
| Gross Profit | 315.50K | 31.27K | 188.87K | 302.20K | 235.69K | 208.00K | 45.00K | - |
| Operating Expenses | - | - | - | - | 6.06M | 7.75M | 3.28M | 5.37M |
| Operating Income | -518.66K | -1.93M | -1.35M | - | -5.82M | -7.54M | -3.28M | -5.37M |
| EBITDA | - | - | - | - | -5.76M | -7.24M | -4.21M | -3.42M |
| Interest Expense | - | - | - | 8.34K | - | 0 | 93.00K | 114.00K |
| Pretax Income | - | - | - | - | -5.78M | -7.26M | -4.32M | -3.61M |
| Tax Provision | - | - | - | - | - | - | 0 | -18.00K |
| Net Income | -356.89K | -1.97M | -1.59M | - | -5.74M | -6.52M | -5.19M | -4.00M |
| Diluted EPS | - | - | - | - | -2,658.25 | -1,330.35 | -194.18 | -60.27 |
| R&D Expense | 357.08K | 615.62K | 417.00K | 538.68K | 770.83K | 1.94M | 369.00K | 179.00K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 859.21K | 664.67K | 687.65K | - | 6.49M | 7.24M | 5.46M | 20.41M |
| Current Assets | - | - | - | - | - | 6.27M | 5.47M | 3.45M | 6.01M |
| Cash & Equivalents | - | 439.81K | 290.81K | 242.90K | - | 5.70M | 4.45M | 1.92M | 3.83M |
| Inventory | - | - | - | - | 22.60K | 81.71K | 122.00K | 21.00K | - |
| Receivables | - | - | - | - | - | 192.60K | 107.00K | 137.00K | 134.00K |
| Total Liabilities | - | 647.70K | 1.07M | 1.15M | - | 754.87K | 786.00K | 892.00K | 4.67M |
| Current Liabilities | - | 483.70K | 623.83K | 785.23K | - | 714.85K | 779.00K | 892.00K | 1.43M |
| Long Term Debt | - | 37.93K | 14.96K | 8.12K | - | - | - | - | 237.00K |
| Total Debt | - | - | - | - | - | 106.33K | 48.00K | 7.00K | 992.00K |
| Total Equity | -743.46K | 218.23K | -381.07K | -436.18K | - | 5.85M | 6.48M | 4.75M | 16.01M |
| Shares Outstanding | - | - | - | - | - | 2.69K | 12.06K | 49.22K | 396.13K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -506.50K | -1.24M | -798.74K | - | -5.10M | -3.23M | -3.42M | -3.81M |
| Investing Cash Flow | 5.78K | -81.66K | -6.73K | - | -51.69K | -1.52M | -1.89M | -3.23M |
| Financing Cash Flow | 912.21K | 1.18M | 741.76K | - | 4.09M | 3.47M | 3.05M | 8.86M |
| Capital Expenditure | -2.53K | -23.33K | - | -67.75K | -51.69K | - | - | -14.00K |
| Free Cash Flow | -509.03K | -1.27M | - | - | -5.15M | -3.23M | -3.42M | -3.82M |
| Net Change in Cash | - | - | - | - | -1.05M | -1.28M | -2.26M | 1.81M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 74.0% | 17.8% | 81.3% | - | 59.8% | 79.1% | - | - |
| Operating Margin % | -121.6% | -1,098.4% | -580.9% | - | -1,477.1% | -2,865.8% | - | - |
| Net Margin % | -83.7% | -1,121.3% | -685.9% | - | -1,456.7% | -2,479.8% | - | - |
| ROE % | -163.5% | 517.3% | 365.3% | - | -98.2% | -100.6% | -109.3% | -25.0% |
| ROCE % | -138.1% | -4,728.5% | 1,382.8% | - | -100.7% | -116.6% | -71.8% | -28.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 3.11% | 45.24K | $59.26K |
| 2 | Yorkville Advisors Global, LP | 1.13% | 16.41K | $21.50K |
| 3 | Vanguard Fiduciary Trust Co | 0.07% | 998 | $1.31K |
| 4 | Tower Research Capital LLC (TRC) | 0.05% | 736 | $964 |
| 5 | SBI Securities Co., Ltd. | - | 32 | $41 |
| 6 | Barclays Plc | - | 1 | $1 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NXTS
Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS)
Nexentis Technologies Inc. (NASDAQ:NXTS) shares advanced 10% on Monday after the company announced the partial monetisation of its investment in the Melz solar project in Germany, based on a project valuation of US$14.…
Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment
Neve Yarak, Israel, June 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business mode…
Top Midday Gainers
Nexentis Technologies (NXTS) said Monday its subsidiary, MitoCareX Bio, has entered into an engageme
Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign
Following its broad structural analysis of the human SLC transport protein family, MitoCareX advances from a pool of candidates to a prioritized target, reflecting continued execution of its MITOLINE®-driven discovery strategy Ness Ziona, I…
Nexentis Subsidiary MitoCareX Bio Advances SLC Transporter Drug Discovery with Broad Analysis and International AI Initiative
MitoCareX Bio completes comprehensive SLC transport protein analysis to support discovery of small molecules for hard-to-treat cancers and inflammatory metabolic diseases and enters an AI-driven small-molecule discovery initiative with Bolt…
Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery
MITOLINE®-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets Neve Yarak, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Nexentis Techn…
NXTS — Frequently Asked Questions
What is the current share price of Nexentis Technologies Inc. (NXTS)?
As of 2026-09-19 21:16 PDT, Nexentis Technologies Inc. (NXTS) trades at $1.67 on NasdaqCM. Its 52-week range is $1.48 to $58.06.
What is the market capitalisation of NXTS?
Nexentis Technologies Inc. (NXTS) has a market capitalisation of $2.43M on NasdaqCM.
What is the P/E ratio of NXTS?
NXTS trades at a trailing price-to-earnings (P/E) ratio of 0.20. The industry average P/E is 22.16. Its price-to-book (P/B) ratio is 1.00.
Is NXTS a good stock to buy?
This page provides a data-driven analysis of Nexentis Technologies Inc. (NXTS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.